157 related articles for article (PubMed ID: 23966294)
1. Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction.
Kudo-Saito C; Fuwa T; Murakami K; Kawakami Y
Cancer Res; 2013 Oct; 73(20):6185-93. PubMed ID: 23966294
[TBL] [Abstract][Full Text] [Related]
2. Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.
Kudo-Saito C; Ishida A; Shouya Y; Teramoto K; Igarashi T; Kon R; Saito K; Awada C; Ogiwara Y; Toyoura M
Cell Rep; 2018 Aug; 24(7):1790-1801. PubMed ID: 30110636
[TBL] [Abstract][Full Text] [Related]
3. Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity.
Kudo-Saito C; Fuwa T; Kawakami Y
Eur J Cancer; 2016 Jul; 62():54-61. PubMed ID: 27208904
[TBL] [Abstract][Full Text] [Related]
4. Follistatin-like 1 deficiency impairs T cell development to promote lung metastasis of triple negative breast cancer.
Ma J; Yang Y; Wang L; Jia X; Lu T; Zeng Y; Liu L; Gao Y
Aging (Albany NY); 2021 Feb; 13(5):7211-7227. PubMed ID: 33639614
[TBL] [Abstract][Full Text] [Related]
5. FSTL1 promotes bone metastasis by causing immune dysfunction.
Kudo-Saito C
Oncoimmunology; 2013 Nov; 2(11):e26528. PubMed ID: 24482748
[TBL] [Abstract][Full Text] [Related]
6. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.
Ogiwara Y; Nakagawa M; Nakatani F; Uemura Y; Zhang R; Kudo-Saito C
Cancer Lett; 2022 Jul; 537():215690. PubMed ID: 35439537
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis.
Chan QK; Ngan HY; Ip PP; Liu VW; Xue WC; Cheung AN
Carcinogenesis; 2009 Jan; 30(1):114-21. PubMed ID: 18796737
[TBL] [Abstract][Full Text] [Related]
8. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
9. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.
Kudo-Saito C; Shirako H; Takeuchi T; Kawakami Y
Cancer Cell; 2009 Mar; 15(3):195-206. PubMed ID: 19249678
[TBL] [Abstract][Full Text] [Related]
10. Platelet and osteoclast beta3 integrins are critical for bone metastasis.
Bakewell SJ; Nestor P; Prasad S; Tomasson MH; Dowland N; Mehrotra M; Scarborough R; Kanter J; Abe K; Phillips D; Weilbaecher KN
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14205-10. PubMed ID: 14612570
[TBL] [Abstract][Full Text] [Related]
11. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases.
Chaly Y; Hostager B; Smith S; Hirsch R
Immunol Res; 2014 Aug; 59(1-3):266-72. PubMed ID: 24838142
[TBL] [Abstract][Full Text] [Related]
12. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2.
Chang MR; Lee WH; Choi JW; Park SO; Paik SG; Kim YS
Exp Mol Med; 2005 Jun; 37(3):240-9. PubMed ID: 16000879
[TBL] [Abstract][Full Text] [Related]
13. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer.
Hamanishi J; Mandai M; Matsumura N; Baba T; Yamaguchi K; Fujii S; Konishi I
Stem Cells; 2010 Jan; 28(1):164-73. PubMed ID: 19911426
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
15. Follistatin-like protein 1 regulates chondrocyte proliferation and chondrogenic differentiation of mesenchymal stem cells.
Chaly Y; Blair HC; Smith SM; Bushnell DS; Marinov AD; Campfield BT; Hirsch R
Ann Rheum Dis; 2015 Jul; 74(7):1467-73. PubMed ID: 24641944
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells.
Sohara Y; Shimada H; Minkin C; Erdreich-Epstein A; Nolta JA; DeClerck YA
Cancer Res; 2005 Feb; 65(4):1129-35. PubMed ID: 15734993
[TBL] [Abstract][Full Text] [Related]
17. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
Iwamoto H; Ojima T; Hayata K; Katsuda M; Miyazawa M; Iida T; Nakamura M; Nakamori M; Iwahashi M; Yamaue H
Int J Cancer; 2014 Jan; 134(2):332-41. PubMed ID: 23824921
[TBL] [Abstract][Full Text] [Related]
18. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
Zhao Y; Bachelier R; Treilleux I; Pujuguet P; Peyruchaud O; Baron R; Clément-Lacroix P; Clézardin P
Cancer Res; 2007 Jun; 67(12):5821-30. PubMed ID: 17575150
[TBL] [Abstract][Full Text] [Related]
19. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
Wang XY; Kazim L; Repasky EA; Subjeck JR
Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
[TBL] [Abstract][Full Text] [Related]
20. Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation.
Zhao W; Han HB; Zhang ZQ
Int J Biochem Cell Biol; 2011 Oct; 43(10):1459-68. PubMed ID: 21718795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
